Navigation Links
Epigenomic abnormalities predict patient survival in non-Hodgkins lymphoma
Date:1/10/2013

Think of the epigenome like a giant musical mixing board, turning up or down the expression of various genes. A University of Colorado Cancer Center study published today in the journal PLOS Genetics shows that in cancer, not only can genes themselves go bad, but abnormal changes in the epigenetic mixing board can unfortunately change the expression of these genes. Researchers hope to play the role of sound engineers, controlling these harmful epigenomic changes to turn down cancer itself or perhaps sensitize cancers to existing drugs.

The epigenome's primary tool and by far the easiest to study is methylation: it attaches little methyl groups to DNA sequences near the genes to silence or promote their expression.

"Not only do we see more abnormal methylation in non-Hodgkin lymphoma patients than in healthy B-cell populations, but there are three distinct subtypes of the disease in the clinic, each more aggressive than the next. These three clinical trajectories of non-Hodgkins lymphoma were distinctly marked by their levels of abnormal methylation," says Subhajyoti De, PhD, CU Cancer Center investigator and assistant professor at the CU School of Medicine.

In other words, methylation patterns predict patient survival. Here's how it works:

DNA should be methylated in a consistent way you get a certain, standardized amount of methyl "residue" attached to your genes. Sure enough, that's the case in healthy B-cells. Subhajyoti and colleagues show that in cancerous B-cells, the level of DNA methylation from cell to cell varies wildly. And the more wildly the level of DNA methylation varies, the more aggressive is the cancer. It's as if, in the body, you want a consistent epigenome that maintains the methylation of the healthy status quo when a willy-nilly epigenome drops methylation randomly here and there, it promotes non-normal cells, like cancer.

So abnormal methylation is certainly correlated with not only cancer, but with the aggressive behaviors of cancer subtypes. But what exactly is the functional role of this methylation?

"We think that in addition to genetic mutations that cause cancer, epigenetic changes probably play a subtle role that allows the cancer to thrive within our body," Subhajyoti says.

There are drugs that affect the epigenome's ability to methylate and so control genes some of which crescendo or decrescendo the amount of methylation across the board, and some of which affect the amount of methylation on certain genetic products. Does one of these drugs hold the key to muting cancer?

Subhajyoti hopes to find out.

"For the last 50 years, the scientific community pushed to identify the genetic drivers of cancer, but now in the past five or six years we've expanded the search into the epigenome as well," Subhajyoti says. "We now expect to find that both genetic and epigenetic abnormalities are important for initiation and maintenance of cancer."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Epilepsy Leads to More Brain Abnormalities Over Time
2. Insecticide Linked to Brain Abnormalities in Kids
3. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
4. Treatment of childhood OSA reverses brain abnormalities
5. Genome-wide analysis shows previously undetected abnormalities in parents of affected children
6. Gene Mutation Linked to Facial, Skull Abnormalities
7. Brain Scans of Hoarders Show Unique Abnormalities
8. Documenting womens experiences with chromosome abnormalities found in new prenatal test
9. Psychological testing may predict success in soccer
10. Predictors identified for rehospitalization among post-acute stroke patients
11. Can a standard vision test predict nighttime driving performance?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... ZyDoc , a New York-based medical ... Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” has ... usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ natural ...
(Date:12/8/2016)... ... 08, 2016 , ... David J. Dykeman , Ginger Pigott , ... will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in ... the firm’s global Life Sciences & Medical Technology Group have been featured speakers at ...
(Date:12/8/2016)... ... 08, 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 ... the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) ... Dr. Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) ...
(Date:12/8/2016)... California (PRWEB) , ... December 08, 2016 , ... ... has raised an $18M Series B led by Canvas Ventures . Other investors ... capital to scale its mobile platform to serve more consumers who are managing ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coppin Insurance Agency, an insurance and financial ... around the Cape Coral area, is embarking on a charity drive with the goal ... , The Harry Chapin Food Bank of Southwest Florida works to provide fresh and ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016  Hanson Research, an innovative leader in ... diffusion testing instruments for the pharmaceutical industry, announced ... Inc. ("Teledyne"). The move is designed to deepen ... instruments, as well as expand resources for further ... and services. Logo - http://photos.prnewswire.com/prnh/20161208/446988LOGO ...
(Date:12/8/2016)... FRANCISCO , Dec. 8, 2016 ... today announced that it has closed a $23 ... McKesson Ventures and OrbiMed. The company seeks to ... time physicians spend on mandated EHR documentation. The ... scribe service that frees doctors from 3 hours ...
(Date:12/8/2016)... LITTLE FALLS, N.J., Dec. 8, 2016 CANTEL MEDICAL ... net income of $18,800,000, or $0.45 per diluted share, on ... the first quarter ended October 31, 2016. This compares with ... sales of $153,779,000 for the first quarter ended October 31, ... the first quarter ended October 31, 2016 to $21,323,000, or ...
Breaking Medicine Technology: